Salmon S - Search Results

1

The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma.

Rimsza LM, Campbell K, Dalton WS, Salmon S, Willcox G, Grogan TM. Rimsza LM, et al. Among authors: salmon s. Leuk Lymphoma. 1999 Jul;34(3-4):315-24. doi: 10.3109/10428199909050956. Leuk Lymphoma. 1999. PMID: 10439368

2

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study.

Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR, Bonnet JD. Dalton WS, et al. Among authors: salmon ss. Cancer. 1995 Feb 1;75(3):815-20. doi: 10.1002/1097-0142(19950201)75:3<815::aid-cncr2820750311>3.0.co;2-r. Cancer. 1995. PMID: 7828131 Clinical Trial.

3

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.

List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. List AF, et al. Among authors: salmon s. J Clin Oncol. 1993 Sep;11(9):1652-60. doi: 10.1200/JCO.1993.11.9.1652. J Clin Oncol. 1993. PMID: 8102639 Clinical Trial.

4

Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues.

Powis G, Gallegos A, Abraham RT, Ashendel CL, Zalkow LH, Dorr R, Dvorakova K, Salmon S, Harrison S, Worzalla J. Powis G, et al. Among authors: salmon s. Cancer Chemother Pharmacol. 1997;41(1):22-8. doi: 10.1007/s002800050703. Cancer Chemother Pharmacol. 1997. PMID: 9443610

5

Phase II study of recombinant alpha-interferon in malignant melanoma.

Neefe JR, Legha SS, Markowitz A, Salmon S, Meyskens F, Groopman J, Campion M, Evans L. Neefe JR, et al. Among authors: salmon s. Am J Clin Oncol. 1990 Dec;13(6):472-6. doi: 10.1097/00000421-199012000-00004. Am J Clin Oncol. 1990. PMID: 2239801 Clinical Trial.

6

Scientists, media should not overstate 'breakthroughs'.

Salmon S. Salmon S. Ann Oncol. 1998 Aug;9(8):794-5. Ann Oncol. 1998. PMID: 9789598 No abstract available.

7

Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases.

Nelson MA, Radmacher MD, Simon R, Aickin M, Yang J, Panda L, Emerson J, Roe D, Adair L, Thompson F, Bangert J, Leong SP, Taetle R, Salmon S, Trent J. Nelson MA, et al. Among authors: salmon s. Cancer Genet Cytogenet. 2000 Oct 15;122(2):101-9. doi: 10.1016/s0165-4608(00)00281-8. Cancer Genet Cytogenet. 2000. PMID: 11106819

8

Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.

Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TP. Salmon S, et al. J Thorac Oncol. 2009 Jun;4(6):689-96. doi: 10.1097/JTO.0b013e3181a526b3. J Thorac Oncol. 2009. PMID: 19404214 Free PMC article. Clinical Trial.

9

A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin.

Rosenblum MG, Murray JL, Cheung L, Rifkin R, Salmon S, Bartholomew R. Rosenblum MG, et al. Among authors: salmon s. Mol Biother. 1991 Mar;3(1):6-13. Mol Biother. 1991. PMID: 1906286

10

Ex vivo liver resection coupled with associated liver partition and portal vein ligation: Combining existing techniques to achieve surgical resectability.

Baimas-George MR, Levi DM, Eskind LB, Kirks RC, Passeri M, Lessne M, Kardassis D, Salmon S, Iannitti DA, Vrochides D. Baimas-George MR, et al. Among authors: salmon s. J Surg Oncol. 2019 May;119(6):771-776. doi: 10.1002/jso.25375. Epub 2019 Jan 15. J Surg Oncol. 2019. PMID: 30644109

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

533 results

Search Page